© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 3, 213-214,
February 3, 1999
© 1999 Oxford University Press
NEWS |
Awards, Appointments, Announcements
The University of North Texas Health Science Center, Fort Worth, announced that it is forming an Institute for Cancer Research and that Ronald H. Goldfarb, Ph.D., chair of the center's Department of Molecular Biology and Immunology, will be first director of the new institute.The new Institute for Cancer Research will be the fifth specialized institute at the university health center. Others concentrate on aging, heart disease, harmful substances, and human vision, the announcement said.
Lichter Named
The University of Michigan Health System, Ann Arbor, announced that Allen S. Lichter, M.D., became interim dean of the University of Michigan Medical School in December. He is professor of radiation oncology there.
|
The university is searching for a permanent dean to succeed Giles Bole, M.D., who left the post in 1996 to return to teaching and research. A. Lorris Betz, M.D., served as interim dean from 1996 until December, when Lichter was appointed. Betz, after a year-long sabbatical, will return to full-time teaching and research.
NCI Names Coleman
The National Cancer Institute announced that C. Norman Coleman, M.D., has been named chief of its Radiation Oncology Branch, deputy director of NCI's Division of Clinical Sciences, and associate director of the Radiation Research Program in the NCI Division of Cancer Treatment and Diagnosis.
|
Coleman has been since 1985 professor of radiation oncology and chairman of the Joint Center for Radiation Therapy at Harvard Medical School Boston. In addition to managing radiation programs and initiatives at NCI, Coleman will co-direct a coordinated residency training program in radiation oncology that will include fellows from the National Institutes of Health, the National Naval Medical Center, and the Walter Reed Army Medical Center.
Anderson Named President
NeoRx Corp., Seattle, named Dick Anderson as its president and chief operating officer. He had been senior vice president and chief financial officer there since January 1997, and has also been vice president for finance and operations since early 1998.
NeoRx develops therapeutic products for cancer and inflammatory diseases, with an initial focus on multiple myeloma, lymphoma, and atherosclerosis, the announcement said.
Zeneca and Astra Merge
The boards of two pharmaceutical companies, Astra and Zeneca, announced that the companies will merge to form AstraZeneca, with Percy Barnevik as chairman, Tom McKillop as chief executive officer, and Sir David Barnes and Haken Mogren as deputy chairmen.
The company will have corporate headquarters in London and its research and development headquarters in Sweden. The new company is considered to be the third largest in the pharmaceutical industry.
WHO Center
The University of Texas M. D. Anderson Cancer Center, Houston, has been designated as a World Health Organization Collaborating Center in Supportive Cancer Care, one of only six such centers in the world.
Other institutions with the designation are Oxford University, England; Memorial Sloan-Kettering Cancer Center, New York; the WHO Collaborating Center in Cancer Pain and Policy Studies, Madison, Wis.; Institute for Cancer Study and Cure, Milan, Italy; and the Saitama Cancer Center, Japan.
The six centers work to improve standards, impact international health policy, and provide greater access to palliative and supportive care, including pain and symptom management for cancer patients around the world.
Workshop on Risk Communication
Nearly 60 risk experts from the United States and Canada met recently to grapple with the problem of how to communicate cancer risk information in a way that the public will easily understand.
"The workshop provided a forum for focused discussion among researchers, practitioners, institutional communicators, journal editors, and media representatives who communicate information about cancer risk," said Barbara K. Rimer, Dr.P.H., director of NCI's Division of Cancer Control and Population Sciences. "Leading minds in the field clarified the strengths and limitations of various risk communication techniques and channels and set an agenda for research needs."
The workshop proceedings will be published in a monograph to be issued by the Journal of the National Cancer Institute this summer.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||